Scarica l'app Stockscreener
94.09
2.79%
2.55
Precedente Chiudi:
$91.54
Aprire:
$90.85
Volume 24 ore:
232.88K
Relative Volume:
1.27
Capitalizzazione di mercato:
$1.11B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+12.39%
1M Prestazione:
+24.37%
6M Prestazione:
+309.09%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$90.00
$95.43
Intervallo di 1 settimana:
$80.64
$101.94
Portata 52W:
$11.17
$101.94
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
94.09 | 1.08B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Is Frog Cellsat Limited Positioned to Benefit From Secular ShiftsCandlestick Trading Patterns & Discover Your Financial Freedom Formula - earlytimes.in
Palvella Therapeutics stock hits 52-week high at $98.60 By Investing.com - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock rise with strong economyQuarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Raymond James Financial - Defense World
Palvella Therapeutics Inc (PVLA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Why Palvella Therapeutics Inc. stock remains a top recommendationRecession Risk & Low Drawdown Investment Ideas - newser.com
Will Palvella Therapeutics Inc. stock continue dividend increasesWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - newser.com
Can Palvella Therapeutics Inc. stock beat analyst upgradesJuly 2025 Volume & AI Driven Stock Reports - newser.com
Raymond James Upgrades Palvella Therapeutics (PVLA) - Nasdaq
Can momentum traders help lift Palvella Therapeutics Inc.2025 Market Sentiment & AI Driven Stock Movement Reports - newser.com
Raymond James upgrades Palvella Therapeutics stock rating to Strong Buy By Investing.com - Investing.com Canada
Why global investors buy Palvella Therapeutics Inc. (PI6) stockIndex Update & Technical Pattern Based Buy Signals - newser.com
Can Palvella Therapeutics Inc. stock maintain growth trajectory2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Raymond James upgrades Palvella Therapeutics stock rating to Strong Buy - Investing.com India
Can Palvella Therapeutics Inc. stock sustain market leadership2025 Big Picture & Long-Term Capital Growth Ideas - newser.com
What MACD and RSI say about Palvella Therapeutics Inc.Portfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
How geopolitical risks impact Palvella Therapeutics Inc. (PI6) stock2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Can Palvella Therapeutics Inc. stock withstand economic slowdownJuly 2025 Final Week & Technical Pattern Recognition Alerts - newser.com
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly - MyChesCo
Cantor Fitzgerald Issues Negative Estimate for PVLA Earnings - Defense World
Palvella Therapeutics (PVLA) Gets a Buy from LifeSci Capital - The Globe and Mail
Can Palvella Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
Why Palvella Therapeutics Inc. (PI6) stock is favored by hedge fundsInflation Watch & Fast Entry Momentum Alerts - newser.com
Lifesci Capital Has Negative Outlook of PVLA FY2025 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for PVLA Earnings - Defense World
Why Palvella Therapeutics Inc. (PI6) stock is upgraded to buyPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):